Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

GSK, other drugmakers bet on post-Brexit UK science

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06/2017 | 01:21pm CET
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

LONDON (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union.

Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines.

In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations.

That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world's most detailed biomedical database.

GSK's head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned: "The UK needs to recognise going forward that science is an international endeavour, not a parochial endeavour."

Other investments by pharma companies include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials and genetic research by AstraZeneca.

U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week.

In all, the government said the deal brought together existing and future commitments by 25 global organisations.

Other companies in discussions with the government about investments include Philips, Roche Diagnostics, Siemens, GE Healthcare and Toshiba Medical Systems.

As a key part of the deal, the government said it was committed to increasing investment in R&D to 2.4 percent of GDP by 2027 and 3 percent over the longer term.

(Reporting by Ben Hirschler; Editing by Gareth Jones and Louise Heavens)

By Ben Hirschler

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.54% 1296 Delayed Quote.-1.47%
JOHNSON & JOHNSON 1.62% 132.02 Delayed Quote.-7.02%
MERCK AND COMPANY 0.55% 54.87 Delayed Quote.-3.06%
THE MEDICINES COMPANY 4.16% 31.07 Delayed Quote.15.65%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
01:48pASTRAZENECA : Lynparza CHMP for ovarian cancer maintainance
01:47pASTRAZENECA : Lynparza receives positive EU CHMP opinion in platinum-sensitive r..
02/22ASTRAZENECA : FluMist back on CDC's recommended list of flu vaccines
02/22ASTRAZENECA : FDA Approves AstraZenecas Lung Cancer Treatment after Rejecting Me..
02/22ASTRAZENECA : AZ adds another Ionis drug in $330m kidney disease deal
02/21ASTRAZENECA : It's OK to use nasal spray flu vaccine again, US panel says
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
02/21ASTRAZENECA : Announces Renewed Recommendation and Availability of FLUMIST QUADR..
02/21ASTRAZENECA : US panel says it's OK to use nasal spray flu vaccine again
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
More news
News from SeekingAlpha
12:24pArcus Biosciences Files To Raise $100 Million In IPO 
08:54aEuropean advisory group backs expanded use for AstraZeneca's Lynparza 
08:00a3 THINGS IN BIOTECH YOU SHOULD LEARN : February 22, 2018 
02/223 THINGS IN BIOTECH YOU SHOULD LEARN : February 21, 2018 
02/21CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year 
Financials ($)
Sales 2018 22 345 M
EBIT 2018 5 638 M
Net income 2018 2 132 M
Debt 2018 14 076 M
Yield 2018 4,12%
P/E ratio 2018 33,54
P/E ratio 2019 26,48
EV / Sales 2018 4,44x
EV / Sales 2019 4,18x
Capitalization 85 057 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 8,9%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-6.82%85 057
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618